News releases
Date
Language

Type of release


Download

Full announcement
Jul 18, 2012

Novo Nordisk A/S: FDA schedules Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed the company that an FDA Advisory Committee meeting is tentatively scheduled to be held on 8 November 2012 to discuss the New Drug Applications (NDA) for the ultra-long-acting insulin degludec and insulin degludec/insulin aspart.

Further information:


 Media: 		Investors:
Mike Rulis Kasper Roseeuw Poulsen
Tel: (+45) 3079 3573 Tel: (+45) 4442 4303
mike@novonordisk.com krop@novonordisk.com
Frank Daniel Mersebach
Tel: (+45) 4442 0604
fdni@novonordisk.com
Lars Borup Jacobsen
Tel: (+45) 3075 3479
lbpj@novonordisk.com
In North America:
Ken Inchausti Jannick Lindegaard
Tel: (+1) 609 514 8316 Tel: (+1) 609 786 4575
kiau@novonordisk.com jlis@novonordisk.com

Company Announcement No 46 / 2012